XFOR earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -0.81. Updated 2026-07-23.
X4 Pharmaceuticals (XFOR) Research Hub
X4 Pharmaceuticals (XFOR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.25 USD (+0.31%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.81, market cap 0.35B. This hub links to the full technical, earnings and options research available for XFOR.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.25 USD (+0.31%) |
| 52-week range | 2.43 USD – 4.82 USD |
| Trend regime | Range |
| 14-day RSI | 65.4 (Bullish) |
| Trailing P/E | -0.81 |
| Market cap | 0.35B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for XFOR
Covered Call on XFOR: how it works, illustrative setup around the real 3.25 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on XFOR: how it works, illustrative setup around the real 3.25 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on XFOR: how it works, illustrative setup around the real 3.25 USD price, max profit/loss, breakeven and when to use it. Educational.
XFOR technical analysis: range, last 3.25 USD, RSI 65.4, 52w range 2.43 USD–4.82 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is XFOR in?
X4 Pharmaceuticals (XFOR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is XFOR in an uptrend or downtrend?
As of 2026-10-26, XFOR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is XFOR's trailing P/E ratio?
XFOR's trailing P/E is -0.81, with a market cap of 0.35B. See the earnings research page for full valuation detail.
When does XFOR next report earnings?
XFOR is next scheduled to report earnings on 2026-08-06.